Wow. Not to belabor the obvious, but here's the q
Post# of 148190
(Total Views: 856)
Posted On: 12/16/2021 3:46:57 PM
Wow. Not to belabor the obvious, but here's the quote from the link Ohm supplied. Frederick Hayden, of course, was the member of the DSMC for CD12 with links to Gilead. The quote below is from April 2020 -- a quote defending Remdesivir's results.
Okay, that was April 2020. Hayden's pushing Remdesivir in a study he helmed.
In May 2020, based on a small reduction in hospital stay, but no improvement in mortality, Remdesivir got an EUA for severe patients.
In August 2020, authorized use of Remdesivir was expanded.
In October of the same year, Hayden is on DSMC that performs the interim analysis for Leronlimab. The Committee suggests no change in the trial.'
Remember that it was only because of a CHANGE in the primary endpoint that allowed Remdesivir to squeak through its trial. Hayden and company suggest no such change for Leron.
If they had suggested a change similar to the one that was used for Remdeceiver, Leron would have HIT ITS PRIMARY ENDPOINT.
Meanwhile, Gilead's drug has gone on to sell about $6 billion worth in 2020 and 2021. It has never demonstrated a reduction of mortality at all. Not in 14 days, not in 28 days.
I don't even care if I sound like a guy in a tin hat. I look at the above timetable and I get enraged that lives were thrown away so that Gilead could make $6 billion for not helping people, and a drug that could have saved many lives was tied to the starting block with a golden chain.
Foul is Fair, and Fair is Foul.
Quote:
Frederick Hayden, an infectious disease expert at the University of Virginia School of Medicine who helped the Chinese doctors conduct the study, disputed the characterization that the study had failed.
“That is not correct,” Hayden said in an interview, when asked whether the results showed remdesivir had flopped. “My interpretation of them is not consistent with that headline.”
Okay, that was April 2020. Hayden's pushing Remdesivir in a study he helmed.
In May 2020, based on a small reduction in hospital stay, but no improvement in mortality, Remdesivir got an EUA for severe patients.
In August 2020, authorized use of Remdesivir was expanded.
In October of the same year, Hayden is on DSMC that performs the interim analysis for Leronlimab. The Committee suggests no change in the trial.'
Remember that it was only because of a CHANGE in the primary endpoint that allowed Remdesivir to squeak through its trial. Hayden and company suggest no such change for Leron.
If they had suggested a change similar to the one that was used for Remdeceiver, Leron would have HIT ITS PRIMARY ENDPOINT.
Meanwhile, Gilead's drug has gone on to sell about $6 billion worth in 2020 and 2021. It has never demonstrated a reduction of mortality at all. Not in 14 days, not in 28 days.
I don't even care if I sound like a guy in a tin hat. I look at the above timetable and I get enraged that lives were thrown away so that Gilead could make $6 billion for not helping people, and a drug that could have saved many lives was tied to the starting block with a golden chain.
Foul is Fair, and Fair is Foul.
(32)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼